Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV...
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today complete results from its Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus (RSV)...
View ArticleRecent data from Silence Therapeutics’ Atu111 pre-clinical study on acute...
Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company is pleased to announce that recent data in pre-clinical models demonstrated the efficacy of Atu111 in acute lung injury.
View ArticleU.S. District Court rules in favor of Alnylam in patent infringement case...
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. District Court of the District of Massachusetts has ruled in favor of Alnylam and has denied Tekmira...
View ArticleGenzyme, Alnylam partner to develop and commercialize RNAi therapeutics...
Alnylam Pharmaceuticals, Inc. and Genzyme, a Sanofi company, announced today that they have formed an exclusive alliance to develop and commercialize RNAi therapeutics targeting transthyretin (TTR) for...
View ArticleAlnylam third quarter 2012 revenues decrease to $16.8 million
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2012, and company highlights.
View ArticleALN RNAi therapeutic program represents novel approach for treatment of AAT...
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the...
View ArticleAlnylam advances Tuschl II patent estate through the USPTO
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office has issued Notices of Allowance for three patent applications from...
View ArticleAlnylam begins dosing in Phase I clinical trial with ALN-TTRsc for treatment...
Alnylam Pharmaceuticals a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTRsc, an RNAi therapeutic targeting transthyretin (TTR)...
View ArticleAlnylam reports pre-clinical data from ALN-AS1 program for treatment of AIP
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented key pre-clinical proof-of-concept data from its RNAi therapeutic program targeting...
View ArticleAlnylam presents new pre-clinical data of ALN-CC5 for treatment of...
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-CC5, an RNAi therapeutic targeting complement component C5.
View ArticleAlnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH...
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data from its RNAi therapeutic program for the treatment of hemophilia and...
View ArticleAlnylam releases positive top-line data from ALN-TTRsc Phase I trial for...
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive top-line results from its ongoing Phase I trial of ALN-TTRsc, a subcutaneously administered RNAi therapeutic...
View ArticleFDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has granted an Orphan Drug Designation to ALN-AT3...
View ArticleCholesterol-lowering drugs could be alternative treatment for people who take...
A new class of cholesterol-lowering drugs that target a recently discovered regulator of harmful cholesterol could be an alternative or complementary treatment for the 30 million people who take...
View ArticleArrowhead initiates Phase 1 study of ARC-520 for treatment against chronic...
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520,...
View ArticleAlnylam advances Development Candidate for ALN-AS1 for treatment of hepatic...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it is advancing its Development Candidate for ALN-AS1, an RNAi therapeutic targeting...
View ArticleGoInformatics, TeselaGen form strategic partnership to offer cutting-edge...
GoInformatics and TeselaGen have announced a strategic partnership to offer a state-of-the-art Biological Design Automation and Scientific Data Management platform. With a secure repository to collect,...
View ArticleArrowhead files application for start ARC-520 phase 2a trial for chronic...
Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a phase 2a clinical trial...
View ArticleArrowhead reports Phase 1 study data on ARC-520 for treatment of chronic...
Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that COO and Head of R&D, Bruce Given, M.D., presented data on the Phase 1...
View ArticleAlnylam presents new pre-clinical data with ALN-AT3 for treatment of...
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting...
View Article